Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EVMN with free AI briefings, catalyst countdowns, and dilution alerts.

EVMN · Evommune, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$262.3M Cash on Hand
34.1mo Cash Runway
Follow EVMN by email Get an email when EVMN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EVMN, unsubscribe in one click. Privacy

📣 What EVMN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
EVO101 Atopic Dermatitis Eczema Phase 2 · NCT05579899 Completed
EVO301 Atopic Dermatitis (AD) Phase 2 · NCT06723405 Completed
EVO756 Atopic Dermatitis Phase 2 · NCT07150845 Completed
EVO756, Dose 1 Migraine Phase 2 · NCT07616128 Recruiting
EVO756, Dose 2 Migraine Phase 2 · NCT07616128 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EVMN holds $262.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $23.1M/quarter from operations, an estimated runway of 34.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EVMN files for a raise →

👥 Who Owns EVMN

Insiders 37.5% Other 5%+ holders 30.7% Institutions (150 holders) 31.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
7 Cooperative UA LSP
Director, 10% owner
Insider 5,288,313 14.57% 2026-02-17
Weegen Felice Isabel Verduyn-van
Director, 10% owner
Includes shares also reported by 7 Cooperative UA LSP, counted once
Insider 5,288,313 14.57% 2026-02-17
LSP 7 Cooperatieve U.A. 5%+ holder (13D) 5,288,313 14.57% 2026-02-12
RA CAPITAL MANAGEMENT, L.P.
Director
Insider 3,494,638 9.63% 2026-11-06
Nan Fung Group Holdings Limited 5%+ holder (13G) 3,435,599 9.47% 2025-12-31
Robert Lorne Hopfner
Director, 10% owner
Insider 3,372,001 9.29% 2025-12-19
Point72 Asset Management, L.P. 5%+ holder (13G) 2,434,080 6.71% 2026-09-30
Luis C. Pena
President & CEO, Director · +291,420 options
Insider 631,573 1.74% 2026-09-30
Pivotal bioVenture Partners Fund I, L.P.
Director, 10% owner
Insider 294,502 0.81% 2025-11-07
Eugene Bauer
Chief Medical Officer, Director · +151,117 options
Insider 270,818 0.75% 2025-12-09
Janice Suzann Drew
Chief of Dev. Operations · +167,008 options
Insider 67,794 0.19% 2026-06-22
Gregory S. Moss
Chief Business & Legal Officer · +163,124 options
Insider 64,010 0.18% 2026-05-28

Share count 36,292,113 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EVMN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EVMN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.